| 研究課題/領域番号 |
23K15167
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分53020:循環器内科学関連
|
|---|
| 研究機関 | 自治医科大学 |
|---|
研究代表者 |
メタタームタナチャイ 自治医科大学, 医学部, ポスト・ドクター (70910644)
|
|---|
| 研究期間 (年度) |
2023-04-01 – 2025-03-31
|
| 研究課題ステータス |
交付 (2023年度)
|
| 配分額 *注記 |
4,680千円 (直接経費: 3,600千円、間接経費: 1,080千円)
2024年度: 1,820千円 (直接経費: 1,400千円、間接経費: 420千円)
2023年度: 2,860千円 (直接経費: 2,200千円、間接経費: 660千円)
|
|---|
| キーワード | Heart failure / TAC / Pressure overload / heart failure |
|---|
| 研究開始時の研究の概要 |
In this research, β-catenin and KLF5 inhibitors have benefits for preventing heart failure (HF) from pressure overload. Understanding the precise mechanism and target cell types is necessary to clarify the pathway of candidate compounds to develop effective drugs for preventing HF in the future.
|
| 研究実績の概要 |
C57BL/6 male mice were subjected to transverse aortic constriction (TAC) to induce pressure overload. The rate of survival was monitored. Before being euthanized, the mice were subjected to echocardiography to assess ejection fraction (EF), wall thickness, and heart function. Then, after TAC surgery, the mice were subjected to echocardiography to assess the EF. The mice were euthanized and sampled to investigate every 1 week until 4 weeks after TAC. The heart failure-related gene expression was analyzed by qRT-PCR. Next, the expression of proteins in the up and downstream of each pathway was investigated. Some parts of metabolic alteration were measured by Mass spectrometry. The cell target in response to HF prevention will be continued to investigate.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
3: やや遅れている
理由
It takes time to prepare the sample from the TAC-mice model. Now, the tissues from the mice are available for the next step of the experiment.
|
| 今後の研究の推進方策 |
The remaining gene and protein expressions will be performed by qRT-PCR, microarray, and Western blot. Flow cytometry will be used to measure cardiomyocytes, cardiac fibroblasts, and macrophages using immunolabeling or antibody. After identifying the cell target in response to HF prevention, gene expression will be validated and protein expression will be measured and confirmed using Mass spectrometry. Then, the whole metabolic alteration will be measured by Mass spectrometry.
|
